“…In contrast, the enhanced expression of LacdiNAc has been shown to be associated with the progression of human prostate, ovarian, colon, and liver cancers [12,15,16,17]. Therefore, the quantification of LacdiNAc glycan carrying glycoproteins or tissue-specific expression of LacdiNAc glycan detected by the WFA has shown promise as cancer glycobiomarkers [17,18,19]. In particular, regarding PCa, there are only three papers about LacdiNAc distribution in prostate biopsy (Pbx) and RP specimens using WFA [15,16,20], and they did not report the relation between WFA-reactivity in tissues and PCa prognosis.…”